Efficacy and safety of rifabutin in the treatment of pulmonary tuberculosis;Tollerabilita ed efficacia terapeutica della rifabutina nel trattamento della tubercolosi polmonare

Recenti Progressi in Medicina

Volumn 90, Issue 5, 1999, Pages 254-257

  Parola, Daniela ^a   Dell'Orso, Daniela ^a   Giovagnoli, Simonetta ^a   Bianconi, Simone ^a   Terzano, Claudio ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

HIV infection; Multiple drug resistance; Pulmonary tuberculosis; Rifabutin

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFABUTIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANCE; TREATMENT OUTCOME; AIDS RELATED COMPLEX; CHRONIC DISEASE; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; TIME;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTICS, ANTITUBERCULAR; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV-1; HUMANS; MALE; MIDDLE AGED; RIFABUTIN; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 0033125287     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. World Health Organization. Guidelines for tuberculosis treatment in national programmes. Geneva: WHO 1991.
2. Crofton J, Home N, Miller F. Diagnosi e terapia della tubercolosi. Edizione italiana a cura di S. Nardini. EDIAIPO Scientifica.
3. Di Pisa G. Tubercolosi. System ed. 1993: 213-52.
4. Mancini P, Pasqua F, Mazzei L, Olliaro P. Rifabutin treatment for tuberculosis in patients with liver function abnormalities. J Antimicrob Chemother 1992; 30: 242.
5. van der Kooi K, Mottet JJ, Regamey C. Isoniazid is not always the cause of hepatitis during treatment of tuberculosis. Clin Infec Dis 1994; 19: 987-8.
6. Grassi C, Peona V. Use of Rifabutin in the treatment of pulmonary tuberculosis. Clin Infec Dis 1996; 22(suppl 1): S50-4.
7. Gonzalez-Montaner LJ, Natal S, Yonchaiyud P, Olliaro P. Rifabutin for the treatment of newly- diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuber Lung Dis 1994; 74: 341-7.
8. Dickinson JM, Mitchison DA. In vitro activity of rifampicins against rifamicin-resistant M. Tuberculosis and MAIS-complex Mycobacteria. Tubercle 1997; 68: 177-82.
9. McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredel M, Felten MK, Bernard Fourie P. Efficacy and safety of Rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462-7.
10. Brogden RN, Fitton A. Rifabutin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 983-1009.
11. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996; 22 (suppl 1): S3-14.
12. Di Perri G, Cruciani M, Danzi MC. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet 1989; 2: 1502-4.
13. Schwander S, Rusch-Gendes S, Mateega A. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associate tuberculosis. Tuber Lung Dis 1995; 76: 210-8.
14. Murray JF. Tuberculose multiresistente. Rev Pneum Clin 1994; 50: 260-7.
15. Vareldzis BP, Grosset J, de Kantor I. Drug-resistant tuberculosis: laboratory issue. WHO reccommendations. Tubercle and Lung Dis 1994; 75: 1-7.
16. Fujiwara PI, Cook SV, Rutherford CM. A continuing survey of drug-resistant tuberculosis in New York City, April 1994. Arch Intern Med 1997; 157: 531-6.
17. Friden TR, Sterling T, Pablos-Mendez A. The emergence of drug-resistant tuberculosis in New York. N Engl J Med 1993; 328: 521-6.
18. Friden TR, Fine Sherman L, Lay Maw K, Fujiwara PI, Crawford JT. A multi-institutional outbreak of highly drug-resistant tuberculosis. Epidemiology and clinical outcomes. JAMA 1996; 276: 1229-35.
19. Bloch AB, Cauthen GM:, Onorato IM. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271: 665-71.
20. Friedman CR, Stoeckle MY, Kreiswirth BN. Transmission of multidrug-resistant tuberculosis in a large urban settig. Am J Respir Crit Care Med 1995; 152: 355-8.
21. Turett GS, Telzak EE, Toria LV. Improved outcomes for patients with multidrug-resistent tuberculosis. Clin Infect Dis 1995; 21: 1238-44.
22. Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis 1995; 1: 7-150.
23. American Thoracic Society. Control of tuberculosis in the USA. Am Rev Resp Dis 1992; 146: 1623-33.
24. Iseman MD, Starke J. Immigrants and tuberculosis control. N Engl J Med 1995; 332: 1094-5.
25. McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among forcing-born persons in the United States 1986 to 1993. N Engl J Med 1995; 332: 1071-6.